AngioDynamics Q2 Results Top Estimates; Boosts FY26 Net Sales Outlook

AngioDynamics reported Q2 net sales of $79.43 million (up from $72.85M year‑ago) and a GAAP net loss of $6.35 million ($0.15/share), with adjusted EPS of $0.00 versus an adjusted loss of $0.04 in the prior-year quarter. The company raised FY2026 net sales guidance to $312–$314 million (from $308–$313M) while maintaining its adjusted loss per share outlook at $(0.33) to $(0.23); consensus expects a $0.33 loss on $310.27M sales. Management announced CEO Jim Clemmer will retire upon appointment of a successor (anticipated in FY2027) and the board has launched a search, a governance development investors should monitor.

Analysis

Market structure: AngioDynamics (ANGO) is showing demand resilience — Q2 sales $79.4M vs. street $76.4M and FY sales guide raised to $312–314M (vs prior $308–313M), so product end-market demand is stable. Winners are ANGO, OEM suppliers of single-use vascular devices, and distributors; losers are smaller peers with heavier elective-procedure exposure if hospitals re-prioritize spending. Pricing power remains limited (guidance still implies a mid-single-digit top-line beat vs. consensus) so upside is volume-driven rather than margin-led in the near term.

Risk assessment: Key tail risks are CEO succession disruption (Clemmer retiring in FY27), reimbursement/regulatory actions, and a product or supply-chain recall that could swing a cash-constrained small-cap into covenant stress; these are low-probability but high-impact. Immediate (days) risk = volatility around succession commentary; short-term (weeks–months) risk = guidance re-affirmation or cut; long-term (quarters–years) risk = failure to convert revenue growth into EBITDA expansion given current adjusted loss guidance ($0.33–$0.23/sh). Hidden dependency: hospital purchasing cycles and Medicare mix drive realized ASPs and gross margin more than unit volumes.

Trade implications: Constructive tactical longs on ANGO conditional on continued top-line beats — prefer defined-risk options (6–9 month call spreads 10–30% OTM) to buy optionality on a re-rate if margins inflect. If holding equity, hedge CEO/succession risk with 3–6 month 10% OTM puts sized to limit drawdown to ~10–15% of position cost; consider a pair trade long ANGO vs short a larger diversified device name (e.g., MDT or DHR) to isolate small-cap execution upside. Rotate modestly from high-beta elective-centric device names into resilient, single-use consumable names; watch 2H quarterlies for margin trajectory before adding full exposure.

Contrarian angle: Street is narrowly focused on adjusted EPS loss; consensus may under-appreciate continued revenue momentum (guide midpoint ~$313M vs consensus $310M) and potential operating leverage if OpEx discipline continues under a new CEO. A disciplined succession search could trigger short-term volatility and a buying window — if FY sales exceed $314M and adjusted loss narrows by >$0.10 from guide, re-rate to higher multiple is plausible. Conversely, mismanaged succession or a negative reimbursement ruling could compress the multiple quickly, so size positions with that binary risk in mind.

Key Decisions for Investors

• Establish a limited 2–3% portfolio long position in ANGO with a 6–9 month horizon, funded increments on pullbacks >8% intra-week; trim if FY revenue midpoint falls below $311M or adjusted-loss guidance widens beyond $0.40/sh.
• Buy a defined-risk call spread (6–9 month expiry) on ANGO with strikes ~10% and ~30% OTM (ratio width to cost such that max loss ≤2% of portfolio) to capture upside if continued top-line beats and margin inflection occur.
• If owning ANGO stock, purchase 3–6 month protective puts 10% OTM sized to cap downside at ~10–15% of position cost to hedge CEO succession/reimbursement tail risk; reject hedges costing >3% premium of position value.
• Implement a pair trade: long ANGO (size as above) and short an equivalent-dollar position in a large-cap diversified device stock (e.g., MDT or DHR) for 3–9 months to isolate small-cap execution upside; unwind if ANGO underperforms peer by >10% or ANGO revenue misses two consecutive quarters.